HK1223031A1 - 用於降低慢性肾病患者的心力衰竭的枸橼酸铁 - Google Patents

用於降低慢性肾病患者的心力衰竭的枸橼酸铁 Download PDF

Info

Publication number
HK1223031A1
HK1223031A1 HK16111332.6A HK16111332A HK1223031A1 HK 1223031 A1 HK1223031 A1 HK 1223031A1 HK 16111332 A HK16111332 A HK 16111332A HK 1223031 A1 HK1223031 A1 HK 1223031A1
Authority
HK
Hong Kong
Prior art keywords
increase
iron
reduce
kidney disease
chronic kidney
Prior art date
Application number
HK16111332.6A
Other languages
English (en)
Chinese (zh)
Inventor
恩裡克．普拉多蘇
恩里克．普拉多苏
羅恩．本圖爾
罗恩．本图尔
詹姆斯．
詹姆斯．F．奥利维耶罗三世
．奧利維耶羅三世
Original Assignee
凯克斯生物制药公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 凯克斯生物制药公司 filed Critical 凯克斯生物制药公司
Publication of HK1223031A1 publication Critical patent/HK1223031A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/26—Iron; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Inorganic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
HK16111332.6A 2013-11-04 2014-11-03 用於降低慢性肾病患者的心力衰竭的枸橼酸铁 HK1223031A1 (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361899866P 2013-11-04 2013-11-04
US61/899866 2013-11-04
PCT/US2014/063643 WO2015066593A1 (en) 2013-11-04 2014-11-03 Ferric citrate for reducing cardiac failure in chronic kidney disease patients

Publications (1)

Publication Number Publication Date
HK1223031A1 true HK1223031A1 (zh) 2017-07-21

Family

ID=53005244

Family Applications (1)

Application Number Title Priority Date Filing Date
HK16111332.6A HK1223031A1 (zh) 2013-11-04 2014-11-03 用於降低慢性肾病患者的心力衰竭的枸橼酸铁

Country Status (15)

Country Link
US (3) US20160256486A1 (enExample)
EP (2) EP3747432A1 (enExample)
JP (3) JP2016535780A (enExample)
KR (1) KR102392441B1 (enExample)
CN (1) CN105873583A (enExample)
AU (1) AU2014341975A1 (enExample)
BR (1) BR112016009901A8 (enExample)
CA (1) CA2928200A1 (enExample)
EA (1) EA201690926A1 (enExample)
HK (1) HK1223031A1 (enExample)
IL (1) IL245317A0 (enExample)
MX (1) MX2016005734A (enExample)
SG (1) SG11201603091QA (enExample)
TW (2) TWI744215B (enExample)
WO (1) WO2015066593A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2563819C2 (ru) 2009-07-21 2015-09-20 Керикс Байофармасьютикалз, Инк. Лекарственные формы цитрата железа (iii)
HRP20171590T1 (hr) 2013-06-05 2017-12-29 Tricida Inc. Polimeri koji vežu protone za oralnu primjenu
EP3157516A4 (en) 2014-06-22 2017-12-13 Dexcel Pharma Technologies Ltd. Pharmaceutical compositions comprising ferric citrate and methods for the production thereof
PL3229816T3 (pl) 2014-12-10 2020-09-21 Tricida Inc. Polimery wiążące protony do podawania doustnego
EP3452028A4 (en) 2016-05-06 2020-04-15 Tricida Inc. COMPOSITIONS AND METHOD FOR TREATING ACID-BASED DISORDERS
AU2018360867B2 (en) 2017-11-03 2024-12-12 Tricida, Inc. Compositions for and method of treating acid-base disorders
EP3873492A1 (en) 2018-10-29 2021-09-08 Pharmacosmos Holding A/s Treating iron deficiency with ferric carboxymaltose
CN114286682A (zh) * 2019-02-09 2022-04-05 法码科思莫斯控股有限公司 治疗具有心血管不良事件风险的个体的铁缺乏以及用于治疗心房颤动的铁
TW202313072A (zh) * 2021-05-27 2023-04-01 美商凱立克斯生物製藥股份有限公司 檸檬酸鐵之兒科調配物

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE351366B (enExample) * 1965-06-08 1972-11-27 Teikoku Hormone Mfg Co Ltd
US20050203169A1 (en) * 2001-08-06 2005-09-15 Moskowitz David W. Methods and compositions for treating diseases associated with excesses in ACE
TWI335218B (en) 2003-02-19 2011-01-01 Panion & Bf Biotech Inc Ferric organic compounds, uses thereof and methods of making same
US8093423B2 (en) 2003-02-19 2012-01-10 Globoasia, Llc Pharmaceutical-grade ferric organic compounds, uses thereof and method of making same
HUE025264T2 (en) * 2005-08-18 2016-02-29 Panion & Bf Biotech Inc Pharmaceutical-grade ferric citrate for medical use
KR20080094013A (ko) * 2006-01-30 2008-10-22 글로보아시아 엘엘씨 연조직의 석회화 역전, 예방, 지연 또는 안정화 방법
US20090186939A1 (en) * 2006-01-30 2009-07-23 Keith Chan Method of Treating Chronic Kidney Disease
RU2563819C2 (ru) * 2009-07-21 2015-09-20 Керикс Байофармасьютикалз, Инк. Лекарственные формы цитрата железа (iii)
WO2012006473A1 (en) * 2010-07-07 2012-01-12 Ardelyx, Inc. Compounds and methods for inhibiting phosphate transport
SG10201805177PA (en) * 2012-06-21 2018-07-30 Keryx Biopharmaceuticals Inc Use of ferric citrate in the treatment of chronic kidney disease patients

Also Published As

Publication number Publication date
BR112016009901A8 (pt) 2020-04-14
KR20160096597A (ko) 2016-08-16
KR102392441B1 (ko) 2022-05-02
JP2016535780A (ja) 2016-11-17
MX2016005734A (es) 2016-11-08
US20160256486A1 (en) 2016-09-08
JP6828100B2 (ja) 2021-02-10
TW201609088A (zh) 2016-03-16
IL245317A0 (en) 2016-06-30
WO2015066593A1 (en) 2015-05-07
EP3065734A4 (en) 2017-05-17
EP3065734A1 (en) 2016-09-14
CN105873583A (zh) 2016-08-17
CA2928200A1 (en) 2015-05-07
TW202203910A (zh) 2022-02-01
US20250360167A1 (en) 2025-11-27
SG11201603091QA (en) 2016-05-30
AU2014341975A1 (en) 2016-05-19
TWI744215B (zh) 2021-11-01
EA201690926A1 (ru) 2016-09-30
JP2019206562A (ja) 2019-12-05
JP2021073230A (ja) 2021-05-13
EP3747432A1 (en) 2020-12-09
US20190307791A1 (en) 2019-10-10

Similar Documents

Publication Publication Date Title
WO2013192565A3 (en) Use of ferric citrate in the treatment of chronic kidney disease patients
HK1223031A1 (zh) 用於降低慢性肾病患者的心力衰竭的枸橼酸铁
PH12018501969A1 (en) Pharmaceutical composition comprising empagliflozin and uses thereof
MX2014011186A (es) Metodo para mejorar la eficiencia de las transfusiones de sangre.
MX2015013170A (es) Proteinas de union especificas duales dirigidas contra tnf alpha.
WO2009125300A3 (en) Oxygenation procedures for newborns and devices for use therein
MX2020010004A (es) Composicion farmaceutica que comprende empagliflozina, metodos para tratamiento y sus usos.
EA201070553A1 (ru) Антитела к гепцидину и варианты их применения
WO2014089209A3 (en) Blood-brain barrier (bbb) penetrating dual specific binding proteins
PH12015502275A1 (en) Therapuetic uses of empagliflozin
BR112015025955A2 (pt) tratamentos anticancerosos com anticorpos anti-egfr apresentando uma baixa fucosilação
WO2014144280A8 (en) DUAL SPECIFIC BINDING PROTEINS DIRECTED AGAINST IL-1β AND / OR IL-17
Chavez et al. New insights into the regulation of vascular permeability
BR112014009225A2 (pt) uso de micelas de proteína de soro de leite para crianças pequenas em risco de obesidade ou diabetes
ES2543850R2 (es) Uso de complejos metálicos miméticos de SOD como agentes alimentarios y como cosméticos
WO2010119991A3 (en) Anti-hgf antibody combinational cancer therapies
PE20141577A1 (es) Espray para heridas
HK1221916A1 (zh) 使用阿曲生坦用於改善脂质概况的方法
MX2015001508A (es) El uso de antitrombina en la oxigenacion por membrana extracorporea.
MX2016003525A (es) Agentes dirigidos contra una interaccion cis de molecula de orientacion repulsiva a (rgma) /neogenina o balsas lipidicas y uso de los mismos en metodos de tratamiento.
WO2013142153A3 (en) Aptamers to tissue factor pathway inhibitor and their use as bleeding disorder therapeutics
BR112014029308A2 (pt) um método de melhorar a função hepática
NZ725920A (en) Use of ferric citrate in the treatment of chronic kidney disease patients
PH12015501764A1 (en) Food composition and its use against dehydration
UA80889U (ru) Способ дифференциальной диагностики анемий у больных с хроническими заболеваниями внутренних органов